Patients with atopic dermatitis commonly experience ophthalmic complications, and a higher incidence of conjunctivitis has been observed during treatment with dupilumab. We present the case of a 49-year-old woman with persistent severe atopic dermatitis who complained of refractory conjunctivitis associated with dupilumab. Ocular examination showed features of atopic conjunctivitis for which an external topical application to the eyelids of pimecrolimus 10 mg/g cream was prescribed. The patient showed substantial clinical remission after only 12 days. This case was remarkable as the medication applied externally to the eyelid skin was effective in treating the conjunctival involvement possibly due to penetration of pimecrolimus through the eyelid layers. Further studies are needed to support the use of this drug for dupilumab-related conjunctivitis.

Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin / Sernicola, A.; Gattazzo, I.; Di Staso, F.; Giordano, D.; Capalbo, A.; Persechino, F.; Scuderi, G.; Persechino, S.. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - 32:(2019), pp. 1-3. [10.1111/dth.13134]

Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin

Sernicola A.;Gattazzo I.;Di Staso F.;Giordano D.;Capalbo A.;Persechino F.;Scuderi G.;Persechino S.
2019

Abstract

Patients with atopic dermatitis commonly experience ophthalmic complications, and a higher incidence of conjunctivitis has been observed during treatment with dupilumab. We present the case of a 49-year-old woman with persistent severe atopic dermatitis who complained of refractory conjunctivitis associated with dupilumab. Ocular examination showed features of atopic conjunctivitis for which an external topical application to the eyelids of pimecrolimus 10 mg/g cream was prescribed. The patient showed substantial clinical remission after only 12 days. This case was remarkable as the medication applied externally to the eyelid skin was effective in treating the conjunctival involvement possibly due to penetration of pimecrolimus through the eyelid layers. Further studies are needed to support the use of this drug for dupilumab-related conjunctivitis.
2019
atopic dermatitis; eczema; drug reaction; therapy-topical; administration; topical; antibodies; monoclonal; humanized; conjunctivitis; dermatitis; atopic; dermatologic agents; eyelids; female; humans; middle aged; tacrolimus; treatment outcome
01 Pubblicazione su rivista::01a Articolo in rivista
Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin / Sernicola, A.; Gattazzo, I.; Di Staso, F.; Giordano, D.; Capalbo, A.; Persechino, F.; Scuderi, G.; Persechino, S.. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - 32:(2019), pp. 1-3. [10.1111/dth.13134]
File allegati a questo prodotto
File Dimensione Formato  
Sernicola_Treatment-of-refractory_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 597.79 kB
Formato Adobe PDF
597.79 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1338251
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact